Track Syndax Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Syndax Pharmaceuticals, Inc. SNDX · Stock Open Syndax Pharmaceuticals, Inc. in new tab

9.45 USD
EPS
-2.37
P/B
-49.48
ROE
-426.43
Beta
0.45
Target Price
35.45 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-2.37
Book Value-0.19
Price to Book-49.48
Debt/Equity3903.45
% Insiders2.855%
Growth
Revenue Growth0.82%
Estimates
Forward P/E-12.07
Forward EPS-0.78
Target Mean Price35.45

DCF valuation

Model fair value for Syndax Pharmaceuticals, Inc. (SNDX)
Result
Sign in to run the valuation for SNDX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 35.45 USD (low 17.00, high 57.00) · as of 15 Nov 2026
Low 17.00
Mean 35.45
High 57.00
Price 9.45
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Syndax Pharmaceuticals, Inc. Logo Syndax Pharmaceuticals, Inc. Analysis (SNDX)

United States Health Care Official Website Stock

Is Syndax Pharmaceuticals, Inc. a good investment? Syndax Pharmaceuticals, Inc. (SNDX) is currently trading at 9.45 USD. Market analysts have a consensus price target of 35.45 USD. This suggests a potential upside from current levels.

Earnings Schedule: Syndax Pharmaceuticals, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -0.78.

Investor FAQ

Does Syndax Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Syndax Pharmaceuticals, Inc.?

Syndax Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -2.37.

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Exchange Ticker
NMS (United States) SNDX
FRA (Germany) 1T3.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion